Plain-English translation of NCT05130255 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial tested a new cancer treatment called GD2-SADA:177Lu-DOTA complex for patients with advanced cancers that have a specific protein on their surface. The treatment works by combining two parts: one part that finds and attaches to cancer cells, and another part that delivers radioactive material directly to those cells to kill them. Researchers were studying how safe this medication is and what doses work best.
Patients with certain advanced cancers like small cell lung cancer, neuroblastoma, sarcoma, and melanoma often run out of effective treatment options. This medication targets a specific protein found on these cancer cells, offering a new approach for patients whose cancers have come back or stopped responding to other treatments.
The trial had three phases. In the first phase, you would receive one treatment cycle to test safety. In the second phase, eligible patients could receive up to 2 treatment cycles. In the final phase, the doses found to be safe would be given repeatedly, with patients receiving a maximum of 5 treatment cycles. Each treatment involved two medications given several days apart, and you would have regular visits to monitor your health and how your cancer responds.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States